AN overweight in pharmaceuticals led to the Barings UK Growth fund lagging the performance of the UK Equity Income portfolio, according to manager Charles Deptford.
The £37.95m Baring Equity Income trust is first quartile over three years, and second quartile over one year in the IMA Equity Income sector, according to Lipper figures up until November 8, 2006 (bid-to-bid) with returns of 72.55pc and 20.5pc respectively. Deptford’s £68.32m UK Growth fund has not been quite as strong and is second quartile over three years and one year in the IMA All Companies sector, according to Lipper data to November 8, 2006 with returns of 57.66pc and 19.85pc. Both funds contain around 45-50 holdings and Deptford explained that many stocks are held in both ...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
